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Abstract
Purpose—Huntington disease (HD) is an incurable terminal disease. Thus, end of life (EOL) 
concerns are common in these individuals. A quantitative measure of EOL concerns in HD would 
enable a better understanding of how these concerns impact health-related quality of life. 
Therefore, we developed new measures of EOL for use in HD.
Methods—An EOL item pool of 45 items was field tested in 507 individuals with prodromal or 
manifest HD. Exploratory and confirmatory factor analyses (EFA and CFA, respectively) were 
conducted to establish unidimensional item pools. Item response theory (IRT) and differential item 
functioning analyses were applied to the identified unidimensional item pools to select the final 
items.
Results—EFA and CFA supported two separate unidimensional sets of items: Concern with 
Death and Dying (16 items), and Meaning and Purpose (14 items). IRT and DIF supported the 
retention of 12 Concern with Death and Dying items and 4 Meaning and Purpose items. IRT data 
supported the development of both a computer adaptive test (CAT) and a 6-item, static short-form 
for Concern with Death and Dying.
Conclusions—The HDQLIFE Concern with Death and Dying CAT and corresponding 6-item 
short form, and the 4-item calibrated HDQLIFE Meaning and Purpose Scale demonstrate excellent 
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psychometric properties. These new measures have the potential to provide clinically meaningful 
information about end of life preferences and concerns to clinicians and researchers working with 
individuals with HD. In addition, these measures may also be relevant and useful for other 
terminal conditions.
Keywords
Health-related quality of life; Neuro-QoL; PROMIS; HDQLIFE; Huntington disease; end of life; 
patient reported outcome (PRO)
Huntington disease (HD) is an autosomal dominant neurodegenerative disease that causes 
motor, behavioral, and cognitive impairments; symptoms typically begin in midlife and 
progress to death within 20 years [1; 2]. End of life concerns may begin when patients 
become aware of their at-risk status, and are magnified after predictive testing reveals a gene 
mutation positive status, or after a clinical diagnosis of HD [3]. Experiences with the 
progression of disease and death in other family members [4] impacts the perspectives of at-
risk and affected individuals about their own end of life (EOL) [4] as well as health-related 
quality of life (HRQOL) [3]. Individuals at-risk for HD, as well as those individuals across 
the full range of the HD disease spectrum (including those with no symptoms to those in the 
later stages of the disease), have identified EOL concerns as an important component of 
HRQOL [3]. Specifically, qualitative research in individuals with HD has identified the 
importance of EOL planning (including family planning, financial planning, and planning 
for palliative care) and concerns about how EOL affects the entire family (both in watching 
other family members suffer and die from this disease, as well as concerns about the burden 
that their disease may place on other family members) as important components of HRQOL 
[3]. A quantitative measure of EOL concerns in HD would facilitate our understanding of 
their relevance to HRQOL, and of their sensitivity to treatments or interventions [5-9]. An 
ideal HD-specific EOL measure should be appropriate for patients at all stages of the disease 
process, from the pre-symptomatic or prodromal period, to the late stages when cognitive 
decline may impact comprehension and judgment about EOL issues [10]. Such a tool could, 
in turn, assist health care providers in initiating discussions about EOL decision-making, 
help them to determine at what point patients would be most receptive to EOL discussions, 
[11] and increase their understanding about how EOL beliefs change over the disease course 
[12].
Several measures exist which were originally intended to measure HRQOL, but these 
measures were either developed for use in other diseases such as cancer, (e.g., revised 
Hospice Quality of Life Index [13]; Death and Dying Distress Scale [14; 15]; McGill 
Quality of Life Questionnaire [16; 17]; QUAL-EC [18]) or are overly generic (e.g., 
CANHELP Lite [19]; EOL-PRO [20]; the Missoula-VITAS quality of life index [21]; 
Palliative Patients’ Dignity Scale [22]; Patient Needs Assessment in Palliative Care [23]; 
Valuation of Life [24]; QUAL-E [25]). These tools do not capture EOL concerns specific to 
HD (e.g., concerns related to watching other family members suffer from and die from the 
disease; concerns about the burden of having HD places on other family members; concerns 
about your children inheriting the disease from you; the fact that there is a gene test that can 
accurately predict who will get symptoms, but not when), take too long to implement (i.e., 
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the CANHELP [26]), and/or include substandard psychometric properties [6-8]. In addition, 
all of these measures neglect to address concerns about EOL impact on HRQOL during the 
earlier stages of a neurodegenerative disease.
To address these shortcomings, this study focused on developing new measures that could 
capture the EOL concerns reported by individuals with HD, their caregivers, and clinical 
providers [3]. Specifically, we used state-of-the-science psychometric methods to create 
calibrated item banks that are comprised of numerous items that allow for administration as 
either a computerized adaptive test (CAT) or as a static short form; administration options 
that provide accurate measurement with low response burden [27]. Below, we highlight the 
development of two new measures of EOL concerns, which are part of a new measurement 
system, the HDQLIFE [28].
Methods
Individuals with prodromal or manifest HD were invited to participate in this study. 
Participants were at least 18 years old, able to read and understand English, and had either a 
positive test for the CAG expansion for HD (HD is a caused by an expansion of CAG 
repeats in the HD gene [HTT]) and/or a clinical diagnosis of HD, and had the ability to 
provide informed consent. In cases where there were concerns about the cognitive capacity 
of a potential participant, the Orientation Log – HD (O-Log-HD) was administered. The O-
Log-HD was adapted from the Orientation Log (O-Log) [29] and provides an assessment of 
mental status; possible scores range from 0-30 and participants with scores < 25 were not 
eligible to participate in the study. Participants were recruited from several specialized HD 
treatment centers (the University of Michigan, the University of Iowa, the University of 
California-Los Angeles, Indiana University, Johns Hopkins University, Rutgers University, 
Struthers Parkinson's Center, and Washington University), through electronic medical 
records [30], the National Research Roster for Huntington's Disease, and articles/
advertisements in HD-specific newsletters and websites. Additionally, the majority of the 
prodromal HD participants in this study were recruited through the Predict-HD study 
[31-33], a longitudinal prospective study (over 30 sites worldwide), examining the clinical 
markers of prediagnostic (i.e., prodromal) HD; this cohort includes over 700, well-
characterized individuals with prodromal HD.
HDQLIFE End of Life Item Pool
Sixty-nine items that examined concerns with EOL were developed through an iterative 
process [28]. Item content was derived in conjunction with the Neuro-QoL project [34], and 
was comprised of literature reviews [34; 35], as well as focus group data in HD, and expert 
input [3]. Items were refined through expert review, translatability review, and cognitive 
interviews with individuals with HD following established methodology [36]; Figure 1 
documents this iterative process. The final item pool was comprised of 45 items.
Participant Characterization
The Total Functional Capacity (TFC) scale [37] from the United Huntington's Disease 
Rating Scales (UHDRS) [38] was administered to all participants. The TFC is a clinician 
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administered 5-item scale designed to evaluate day-to-day functioning across the domains of 
occupation, finances, domestic chores, activities of daily living, and care level. Scores range 
from 0 to 13 with higher scores indicating better functioning. Participants with an HD 
diagnosis were classified as either early-stage (TFC sum scores of 7-13; Stages 1 and 2) or 
later-stage HD (TFC sum scores of 0-6; Stages 3-5).
Analysis Approach
Unidimensionality—Factor analyses were used to establish the unidimensionality of the 
item pool. First, our sample was randomly divided into two data sets. Exploratory factor 
analysis (EFA) with a PROMAX rotation was used to determine number of factors within 
the item pool according to Eigenvalues (> 1) and the number of factors before the break in 
the scree plot. Item loadings were used to determine items and their associated factor 
(criterion > 0.4). Confirmatory factor analysis (CFA) for robust weighted least square 
estimation for ordinal data was then conducted to confirm the factor structure determined 
based on the EFA results [39; 40]. Good fit was established as a comparative fit index (CFI) 
> 0.90, Tucker Lewis Index (TLI) > 0.95, root mean square error of approximation 
(RMSEA) <0.1 [41-44], and residual correlations < .15 (i.e., maintain local independence) 
[45-47]; fit indices meet established standards for CFA when it is applied to PRO 
development [47]. In addition, Cronbach's alpha was examined to determine acceptable 
reliability of the measure (i.e., > .80). EFA and CFA analyses were conducted using MPLUS 
6.11 [48].
Item Response Theory (IRT) Anlayses—The finalized item pools were then calibrated 
using Samejima's graded response model (GRM) [49]; these analyses were conducted in 
IRTPRO 2.1 [50]. This analysis estimated item threshold and item slope parameters, which 
were then used to calculate information functions at the level of individual items and at the 
level of the entire item bank, to characterize measurement precision on the measurement 
continuum at both item and scale levels. Differential item functioning (DIF) was used to 
evaluate stability of measurement properties for each individual item between sub-groups by 
using IRT scaled-score based ordinal logistic regression [51]. DIF analyses were conducted 
using the LORDIF package within R (Version 0.3-2) [52]. DIF was evaluated on gender, age 
(≤ 40 vs. >40 years; ≤50 vs. >50 years), and education (high school graduate or less vs. > 
high school). Items with DIF (non-negligible DIF criterion: R2 > 0.02 and p<.01) were 
discussed by the study team and were candidates for exclusion. Firestar CAT simulation 
software [53] was used to conduct simulation analyses to: 1) determine the number of items 
administered by the CAT for different ability levels for the trait; and 2) examine the 
relationship between the simulated CAT score and scores derived using all items in the bank.
Other Demographic Comparisons—We collected demographic information on age, 
gender, education, and race. Pearson correlations between the new HDQLIFE measures and 
demographic variables (i.e., age and education) were examined. In addition, an independent 
sample t test was conducted to determine if there were significant gender differences for 
these HDQLIFE measures.
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Sample Size Considerations—Study sample size was determined based on sample size 
requirements for IRT, DIF, EFA and CFA analyses. When using Graded Response Models 
(GRM), larger sample sizes produce more stable parameter estimation [49; 54]. In general, 
established standards suggest that a minimum of 5-10 individuals are needed for every item 
within an item pool in order to establish stable parameter estimates [55-57]; thus 500 
individuals were needed for reliable item response theory (IRT) calibration data. Established 
standards for differential item functioning (DIF) analyses (an indication of item bias) 
suggest that at least 200 participants are needed within each condition; considering these 
parameters, sampling stratification targeted age (< 40 vs. ≥ 40 and <50 vs. ≥ 50), gender 
(male vs. female), and education (< high school vs. ≥ high school]) [58]. Finally, EFA and 
CFA analyses recommend the inclusion of ~5 people per item analyzed [55; 57]; thus 250 
individuals were needed for EFA and CFA analyses, respectively (5 individuals for ~50 
items per item pool).
Results
Five hundred seven (507) individuals with prodromal or manifest HD participated in this 
study. Participants were sampled to represent the entire continuum of HD symptomatology; 
196 individuals had prodromal HD (CAG > 35, but did not yet have an HD clinical 
diagnosis), 193 had early-stage HD (sum scores of 7-13 on the TFC), 117 had later-stage 
HD (sum scores of 0-6 on the TFC), and 1 participant was not classifiable. Participants 
ranged in age from 18-81 years (M = 49.01, SD = 13.21) and 40.8% of participants were 
male. Significant differences were seen for age (as symptoms are progressive with age), F 
(2, 503) = 47.360, p< .0001, with individuals who were prodromal (M = 42.60, SD = 12.04) 
being significantly younger than the early-HD group (M = 51.91, SD = 12.41) and the late-
HD group (M = 55.07, SD = 11.89). The early-HD group was also significantly younger 
than the late-HD group. Groups did not differ on gender, Χ2 (2, N = 506) = 3.193, p = .20. 
The majority of participants were Caucasian (96.4%); 2.0% were African American, 1.4% 
were classified as “other,” and 0.2% were unknown. Participants’ education ranged from 4 
to 26 years (M = 15.06, SD = 2.88). While there were group differences in education, F (2, 
501) = 14.781, p< .0001, these differences were small; early- (M = 14.74, SD = 2.78) and 
late-HD (M = 14.22, SD = 2.62) had 1 to 1.5 years less education relative to the prodromal 
HD group (M = 15.88 years, SD = 2.94).
Unidimensionality
Exploratory Factor Analyses (EFA)—Findings based on a random sample of 254 
individuals indicated that the data could largely be explained by 4 factors (Table 1); the first 
factor included 14 items that generally represented meaning and purpose; the second factor 
included only two highly-similar items concerning family members who had died of HD; the 
third factor included 12 items that generally represented anxieties and worries concerning 
death; the fourth factor included 16 items that generally represented thoughts concerning 
death and dying; and finally, 1 item did not load on any of the four factors. Because of the 
spurious nature of the second factor, and the fact that there is an existing PROMIS measure 
concerning anxiety, we elected to focus on developing measures that reflected meaning and 
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purpose (factor 1) and death and dying (factor 4). For the remainder of analyses, we focused 
solely on these two factors.
Confirmatory Factor Analysis (CFA)—Using the second random sample of 253 
individuals, CFAs were conducted separately on each of the two subdomains (i.e., meaning 
and purpose and death and dying) to confirm unidimensionality.
Meaning and Purpose—Content considerations and large residual correlations caused us 
to reduce the number of items for this scale to 7 from 14 items. Results indicated that all 7 
items examining meaning and purpose generally fit the data well; CFI = 0.99, TLI = 0.98, 
RMSEA = 0.11, all r2 > .03. Additionally, all residual correlations were ≤ 0.11 and all item-
total correlations were > 0.4. Cronbach's alpha for this measure was 0.84.
Death and Dying—Examination of all 16 items examining difficulties with death and 
dying revealed 3 items with large residual correlations. These items were deleted resulting in 
13 final items; all residual correlations were ≤ 0.15 for these items. These 13 items were 
then examined using a 1 factor CFA; the analysis for these 13 items yielded a CFI = 0.97, 
TLI = 0.96, RMSEA = 0.15, all r2 > .03. All item-total correlations were > 0.4. Cronbach's 
alpha for this scale was 0.94.
IRT Analyses
Meaning and Purpose—The seven selected items were analyzed using graded response 
model (GRM) [54], in accordance with PROMIS recommendations [50]. IRT parameter 
estimates indicated slopes ranging from 0.84 to 4.75 and thresholds ranging from −3.26 to 
1.78 (See Table 2). S-X2 model fit statistics were examined using IRTPRO; although 5 items 
had misfit statistics (p < 0.05) they were included for further consideration. Information was 
good (i.e., marginal reliability = 0.83), for scale scores between −3 and 0.5 (see Figure 2 for 
the scale information function). No items showed DIF on age, gender, or education. Items 
with slopes < 2.0, as well as misfit statistics, were omitted from the final item set (“I feel 
comfortable talking about my death;” “I find meaning in my illness;” and “There are 
important things that I still want to do with my life”). Thus, 4-items were retained for 
inclusion in this scale and a static short form (instead of a computer adaptive test) was 
developed.
Concern with Death and Dying—One item, “I feel in control of my life” was deleted 
due to a poor slope (0.98). The remaining 12 items indicated slope parameters ranging from 
1.48 to 4.57 and threshold parameters ranging from −0.98 to 3.65 (Table 3). Information was 
good (i.e., reliability ≥ .80), for scale scores between −1.5 and 3.0 (see Figure 3 for the scale 
information function). Although S-X2 indicated that 5 of the 12 items had misfit (p < 0.05); 
these items were retained for further consideration. Marginal reliability was 0.91. DIF was 
not found for age (<50 vs. ≥50 or <40 vs. ≥40), gender (male vs. female), or education 
(some college and lower vs. college degree and higher). A 6-item calibrated Concern with 
Death and Dying short form was then created based on information of slope parameters, 
item characteristic curves, item information, and average item difficulty, as well as input 
from HD and measurement development experts on clinical characteristics (e.g., items were 
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selected that represent different important clinical components of concerns with death and 
dying). Specifically, we balanced the psychometric considerations with clinical content to 
ensure representativeness of the items that were selected for the short form.
Simulation results showed that the average number of items administered to 10,000 virtual 
respondents by the Firestar CAT simulation software was 7.02. The correlation between the 
CAT scores and the full item-bank was 0.99, indicating that the CAT based on the Concern 
with Death and Dying item bank can produce results that are very similar to those obtained 
with administration of the entire 12-item set. Figure 4 shows the number of CAT items used 
for different scale scores in standard deviation units: at −1 SD units, the CAT always used all 
12 items in the item bank; at +1 and +2 SD units, the CAT always used the minimum 
number of 4 items in the item bank; and at 3 SD units the CAT used all 12 items in the item 
bank. Thus, the CAT simulation indicates that fewer items were needed to estimate scores 
for individuals with greater concern with death and dying than for individuals with less 
concern with death and dying.
Scoring of Short Forms
The IRT-scaled scores (theta) were converted into a standardized score utilizing a t score 
(mean = 50, SD = 10; referenced to the HD population represented by the current sample); 
see Table 4 and 5 for a summed score scale conversion table for the short forms for Meaning 
and Purpose, and Concern with Death and Dying, respectively. Higher scores indicate more 
of the construct (i.e., higher scores for Meaning and Purpose indicate greater meaning and 
purpose in ones’ life, whereas higher scores on Concern with Death and Dying, indicate 
greater concerns or preoccupation with death and dying).
Other Demographic Comparisons
There was a small, but significant negative relationship between age and HDQLIFE Concern 
with Death and Dying (r = −.12, p = .009); there was no relationship between age and 
HDQLIFE Meaning and Purpose (r = .05, p = .24). Relationships between education and 
HDQLIFE Concern with Death and Dying (r = .01, p = .76), and education and HDQLIFE 
Meaning and Purpose (r = −.07, p = .10) were negligible. Independent samples t test 
indicated that women (M = 50.92; SD = 9.39) report more Concern with Death and Dying 
than men (M = 48.80; SD =8.24), t(493) = −2.59, p = .01; there were no differences between 
men (M=49.46; SD = 9.28) and women (50.42; SD 8.97) for Meaning and Purpose, t(493) = 
−1.16, p = .25.
Discussion
This paper presents the development of two new patient reported outcomes measures from 
HDQLIFE [28] that evaluate end of life concerns in HD: Meaning and Purpose, and Concern 
with Death and Dying. Analyses supported the development of a 4-item calibrated scale to 
capture Meaning and Purpose, and an item bank that can be administered as either a CAT or 
a 6-item short form to capture Concern with Death and Dying. These are the first measures 
of EOL that have been developed specifically for use in HD and include the first CAT for 
use in evaluating patient reported outcomes regarding EOL concerns. CAT allows for a 
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much briefer approach towards assessment, in that only the most relevant items are 
administered; item selection is based on the participants’ previous response. Furthermore, 
these measures are scored using a t metric, with a mean of 50 and standard deviation of 10; 
higher scores indicate more of the construct (i.e., higher scores for Meaning and Purpose 
indicate greater meaning and purpose in ones’ life, whereas higher scores on Concern with 
Death and Dying indicate greater concerns or preoccupation with death and dying). This 
approach allows for an estimation of an individual's functioning relevant to the reference 
group (in this case, other individuals with HD). For example, scores of 60 or greater on 
Concern with Death and Dying indicate that the individual is more preoccupied with these 
thoughts than 68.27% of people with HD. Scores above 70 indicate thoughts/preoccupation 
with death and dying that exceed 95.45% of individuals with HD. Given the fact that talking 
about these issues can be uncomfortable for both the patient and the provider [59], that 
individuals with HD often do not discuss these concerns with physicians [60], that 
physicians often neglect to initiate discussions about EOL options with patients [61; 62], and 
that this has been recognized as a priority area for HD clinical care [10; 60; 61; 63], these 
measures may serve as a catalyst to help initiate these difficult conversations between 
patients and providers. Furthermore, scores on these measures may potentially serve as 
referents for making appropriate clinical referrals for palliative care services and to identify 
distressed individuals who might benefit from consultation with mental health services 
and/or pastoral counselors.
There is no cure for HD; thus, all HD care is essentially palliative. There are many evidence-
based palliative care interventions available to increase HRQOL of persons with HD [4-7]. 
However, denial, stigma, and conflicting family perceptions of what constitutes quality of 
life and a “good death” are barriers to engaging in EOL discussions [64]. HD has some 
unique characteristics that make disease-specific EOL measures critical. Since HD is an 
autosomal dominant genetic disorder (i.e., it runs in families), persons with a positive gene 
test have often witnessed the decline and death of several family members while they 
contemplate their own genetic fate. In addition, people with the HD gene mutation generally 
have normal functioning until mid-life when subtle symptoms begin, and then slowly 
progress to increasing levels of impairment over 15-20 years or more. Our measures are 
designed to evaluate EOL across the entire disease course. This will enable us to better 
understand how beliefs about EOL change over time in people with HD, and how they are 
impacted by their inevitable cognitive decline. Furthermore, the EOL measures developed 
here are suitable for use in later-stage patients, and will help care providers to evaluate the 
needs/wants of these individuals in order to provide a supportive environment during the end 
of life stage of HD. Current healthcare policies do not provide support for long-term 
palliative care [4]. There is also evidence that patients with neurological conditions are less 
likely than other types of patients, such as patients with cancer, to make advanced directives 
or receive palliative care at the end of life [65]. Our HD-specific EOL measures can help 
identify patients who could benefit from palliative care and advance directives decision 
making, as well as identify when patients are likely to be most receptive to these 
interventions.
While this study has a number of strengths, there are also some limitations. Our study 
sample might not be representative of all people with HD. We recruited participants from 
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specialized HD clinical centers and from the PREDICT-HD study. Most persons with HD do 
not have access to specialized HD centers. Participants in the PREDICT-HD study are 
persons who have independently chosen to be tested for the HD gene mutation prior to 
symptom onset [31-33]. It is estimated that less than 25% of persons at risk for HD undergo 
pre-symptomatic genetic testing [66]. Thus, our sample might be more open to discussing 
EOL concerns because they have given consideration to their own futures through seeking 
HD genetic testing. Previous research in HD has indicated that persons with HD may 
demonstrate impaired awareness of their illness state [67]. This could potentially lead to 
them reporting fewer concerns with death and dying as the disease progresses, which would 
be counterintuitive. Thus, including caregiver perspectives in HD studies is important; a 
factor that is not represented by our study design (which focused solely on patient-centered 
outcomes). Future studies, especially those examining individuals in the later stages of the 
disease, should consider including caregivers. Finally, some study participants completed the 
assessments via computers at home and might have received input and assistance from 
others while others completed the assessments in a research setting. Future work should 
consider examining group differences among these responders.
Taken together, these are the first HD-specific measures that have been developed to capture 
EOL issues such as meaning of life and concerns about death and dying over the course of 
HD. In addition, although these measures were developed for use in HD research, they may 
also have utility in the HD clinic, and might be applicable to other conditions that share 
similar characteristics, such as early-onset Alzheimer disease (which shares an autosomal 
dominant inheritance pattern and a progressive course), as well as other common 
neurological diseases that involve behavioral, cognitive, and/or motor symptoms (e.g. 
Parkinson disease, Multiple Sclerosis, Alzheimer's disease). Future efforts should focus on 
validating these new measures in other terminal conditions.
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Figure 1. 
Procedures to develop the new end of life concerns item pool
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Figure 2. HDQLIFE Meaning and Purpose Test Information
In general, we want total information to be > 9.0 and standard error to be < 0.33 (this 
provides a reliability of 0.9). This figure shows excellent total information and standard error 
for Meaning and Purpose scale scores between −3 and 0.5.
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Figure 3. HDQLIFE Concern with Death and Dying Test Information
This figure shows the test information and scale score standard error for different scale 
scores in standard deviation units for the Concern with Death and Dying scale. Information 
was good (i.e., reliability ≥ .80), for scale scores between −1.5 and 3.0.
Carlozzi et al. Page 17
Qual Life Res. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. HDQLIFE Concern with Death and Dying Number of CAT Items by CAT Theta
This figure shows the number of CAT items used for different scale scores in standard 
deviation units: at −1 SD units, the CAT always used all 12 items in the item bank; at +1 and 
+2 SD units, the CAT always used the minimum number of 4 items in the item bank; and at 
3 SD units the CAT used all 12 items in the item bank.
Carlozzi et al. Page 18
Qual Life Res. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Carlozzi et al. Page 19
Ta
bl
e 
1
Ex
pl
or
at
or
y 
Fa
ct
or
 A
na
ly
sis
 R
es
ul
ts 
fo
r t
he
 H
D
QL
IF
E 
En
d o
f L
ife
 C
on
ce
rns
 It
em
 Po
ol
En
d 
of
 L
ife
 C
on
ce
rn
s 
It
em
s
Fa
ct
or
 1
Fa
ct
or
 2
Fa
ct
or
 3
Fa
ct
or
 4
I l
iv
e 
m
y 
lif
e 
to
 th
e 
fu
lle
st.
a
0.
87
0.
16
−
0.
19
0.
22
I a
m
 m
ak
in
g 
th
e 
m
os
t o
ut
 o
f t
he
 ti
m
e 
I h
av
e 
le
ft.
a
0.
83
0.
22
−
0.
18
0.
14
I a
m
 sa
tis
fie
d 
w
ith
 m
y 
ab
ili
ty
 to
 m
ak
e 
th
e 
m
os
t o
ut
 o
f t
he
 ti
m
e 
th
at
 I 
ha
v
e 
le
ft.
a
0.
82
0.
16
−
0.
05
0.
19
I a
m
 sa
tis
fie
d 
w
ith
 m
y 
co
nt
ro
l o
v
er
 m
y 
m
ed
ic
al
 c
ar
e.
a
0.
76
0.
02
0.
08
−
0.
14
I a
m
 sa
tis
fie
d 
w
ith
 m
y 
de
ci
sio
ns
 a
bo
ut
 m
y 
he
al
th
ca
re
.a
0.
74
0.
09
0.
20
−
0.
10
I a
m
 a
t p
ea
ce
 w
ith
 th
e 
fa
ct
 th
at
 I 
w
ill
 d
ie
.a
0.
68
−
0.
31
0.
30
−
0.
12
M
y 
lif
e 
ha
s m
ea
ni
ng
.a
0.
68
0.
07
−
0.
18
0.
31
I a
m
 a
t p
ea
ce
 w
ith
 d
ea
th
.a
0.
65
−
0.
39
0.
30
−
0.
16
I f
in
d 
m
ea
ni
ng
 in
 m
y 
ill
ne
ss
.a
0.
63
−
0.
14
0.
15
−
0.
08
I f
ee
l c
om
fo
rta
bl
e 
ta
lk
in
g 
ab
ou
t m
y 
de
at
h.
a
0.
63
−
0.
22
0.
23
−
0.
23
M
y 
ill
ne
ss
 st
re
ng
th
en
s m
y 
fa
ith
 (s
pir
itu
al 
be
lie
fs,
 re
lig
ion
).a
0.
58
−
0.
10
−
0.
01
−
0.
11
En
d 
of
 li
fe
 p
la
nn
in
g 
is 
im
po
rta
nt
.a
0.
57
−
0.
11
−
0.
15
−
0.
05
Th
er
e 
ar
e 
im
po
rta
nt
 th
in
gs
 th
at
 I 
sti
ll 
w
an
t t
o 
do
 w
ith
 m
y 
lif
e.
a
0.
55
0.
03
−
0.
35
0.
31
M
at
te
rs
 re
ga
rd
in
g 
m
y 
es
ta
te
 a
re
 in
 o
rd
er
.
a
0.
53
0.
10
0.
09
−
0.
14
I t
hi
nk
 a
bo
ut
 m
y 
fa
m
ily
 m
em
be
rs
 w
ho
 d
ie
d 
fro
m
 th
e 
di
se
as
e.
b
0.
04
0.
76
0.
50
−
0.
01
H
ow
 o
fte
n 
di
d 
yo
u 
th
in
k 
ab
ou
t y
ou
r f
am
ily
 m
em
be
rs
 th
at
 h
av
e 
di
ed
 fr
om
 th
is 
di
se
as
e?
b
0.
01
0.
76
0.
56
0.
01
I a
m
 c
on
ce
rn
ed
 w
ith
 h
ow
 m
y 
de
at
h 
w
ill
 im
pa
ct
 m
y 
fa
m
ily
.
a
−
0.
04
0.
16
0.
99
−
0.
16
I a
m
 w
o
rr
ie
d 
ab
ou
t h
ow
 m
y 
fa
m
ily
 w
ill
 d
ea
l w
ith
 m
y 
de
at
h.
a
0.
02
0.
14
0.
96
−
0.
06
I a
m
 w
o
rr
ie
d 
ab
ou
t h
ow
 m
y 
fa
m
ily
 w
ill
 c
op
e 
w
ith
 m
y 
de
at
h.
a
0.
00
0.
16
0.
96
−
0.
11
I w
o
rr
y 
ab
ou
t t
he
 b
u
rd
en
 th
at
 m
y 
di
se
as
e 
pl
ac
es
 o
n 
m
y 
fa
m
ily
 a
nd
 fr
ie
nd
s.a
0.
02
0.
27
0.
71
0.
03
Se
ei
ng
 o
th
er
 p
eo
pl
e 
w
ith
 m
y 
ill
ne
ss
 sc
ar
es
 m
e.
a
0.
06
−
0.
07
0.
67
0.
15
I a
m
 c
on
ce
rn
ed
 a
bo
ut
 le
av
in
g 
so
m
e 
th
in
gs
 u
nf
in
ish
ed
.a
0.
02
0.
08
0.
64
0.
11
Qual Life Res. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Carlozzi et al. Page 20
En
d 
of
 L
ife
 C
on
ce
rn
s 
It
em
s
Fa
ct
or
 1
Fa
ct
or
 2
Fa
ct
or
 3
Fa
ct
or
 4
Se
ei
ng
 o
th
er
 p
eo
pl
e 
w
ith
 m
y 
ill
ne
ss
 m
ak
es
 m
e 
th
in
k 
ab
ou
t m
y 
ow
n
 d
ea
th
.a
0.
01
0.
15
0.
63
0.
16
I f
ee
l l
ik
e 
a 
fin
an
ci
al
 b
u
rd
en
 to
 m
y 
fa
m
ily
.
a
0.
06
0.
08
0.
56
0.
25
I a
m
 a
fra
id
 o
f w
ha
t t
he
 fu
tu
re
 h
ol
ds
 fo
r m
e.
a
0.
14
−
0.
13
0.
54
0.
29
In
 th
e 
pa
st 
7 
da
ys
 h
ow
 o
fte
n 
di
d 
yo
u 
w
o
rr
y 
ab
ou
t t
he
 e
m
ot
io
na
l b
u
rd
en
 th
at
 y
ou
r d
ise
as
e 
pl
ac
es
 o
n 
yo
ur
 fa
m
ily
 o
r f
rie
nd
s?
b
−
0.
14
0.
16
0.
52
0.
37
I a
m
 a
fra
id
 o
f s
uf
fe
rin
g.
a
0.
14
−
0.
18
0.
51
0.
19
I w
o
rr
y 
ab
ou
t m
y 
ch
ild
re
n 
in
he
rit
in
g 
th
is 
di
se
as
e.
a
0.
02
0.
25
0.
46
−
0.
03
In
 th
e 
pa
st 
7 
da
ys
 h
ow
 o
fte
n 
di
d 
yo
u 
w
o
rr
y 
ab
ou
t h
ow
 y
ou
r f
am
ily
 w
o
u
ld
 c
op
e 
w
ith
 y
ou
r d
ea
th
?b
−
0.
11
0.
06
0.
45
0.
48
In
 th
e 
pa
st 
7 
da
ys
 h
ow
 o
fte
n 
di
d 
yo
u 
fe
el
 li
ke
 a
 fi
na
nc
ia
l b
u
rd
en
 to
 y
ou
r f
am
ily
?b
−
0.
08
0.
09
0.
34
0.
46
In
 th
e 
pa
st 
7 
da
ys
 h
ow
 o
fte
n 
di
d 
yo
u 
th
in
k 
ab
ou
t d
yi
ng
?b
−
0.
02
0.
12
−
0.
03
0.
97
In
 th
e 
pa
st 
7 
da
ys
 h
ow
 o
fte
n 
w
er
e 
yo
u 
pr
eo
cc
up
ie
d 
w
ith
 th
ou
gh
ts 
of
 d
yi
ng
?b
−
0.
01
−
0.
03
−
0.
06
0.
94
In
 th
e 
pa
st 
7 
da
ys
 h
ow
 o
fte
n 
di
d 
yo
u 
th
in
k 
ab
ou
t y
ou
r o
w
n
 d
ea
th
?b
0.
00
0.
09
0.
04
0.
90
In
 th
e 
pa
st 
7 
da
ys
 h
ow
 o
fte
n 
w
er
e 
yo
u 
pr
eo
cc
up
ie
d 
w
ith
 th
ou
gh
ts 
of
 d
ea
th
?b
0.
04
0.
00
−
0.
01
0.
90
In
 th
e 
pa
st 
7 
da
ys
 h
ow
 o
fte
n 
di
d 
yo
u 
fe
el
 a
nx
ie
ty
 th
at
 y
ou
 w
o
u
ld
 d
ie
?b
0.
00
−
0.
31
0.
14
0.
80
In
 th
e 
pa
st 
7 
da
ys
 h
ow
 o
fte
n 
di
d 
yo
u 
ta
lk
 to
 o
th
er
s a
bo
ut
 y
ou
r o
w
n
 d
ea
th
?b
−
0.
14
0.
13
0.
04
0.
74
In
 th
e 
pa
st 
7 
da
ys
 h
ow
 o
fte
n 
di
d 
yo
u 
th
in
k 
ab
ou
t e
nd
in
g 
yo
ur
 li
fe
?b
0.
25
0.
20
−
0.
21
0.
74
In
 th
e 
pa
st 
7 
da
ys
 h
ow
 o
fte
n 
di
d 
yo
u 
be
co
m
e 
sa
d 
w
he
n 
yo
u 
th
ou
gh
t a
bo
ut
 th
e 
en
d 
of
 y
ou
r l
ife
?b
−
0.
03
−
0.
21
0.
16
0.
72
In
 th
e 
pa
st 
7 
da
ys
 h
ow
 o
fte
n 
w
er
e 
yo
u 
w
o
rr
ie
d 
yo
ur
 il
ln
es
s w
o
u
ld
 g
et
 w
o
rs
e?
b
−
0.
05
0.
00
0.
22
0.
65
In
 th
e 
pa
st 
7 
da
ys
 h
ow
 o
fte
n 
w
er
e 
yo
u 
af
ra
id
 o
f d
yi
ng
?b
0.
02
−
0.
39
0.
19
0.
64
In
 th
e 
pa
st 
7 
da
ys
 h
ow
 o
fte
n 
w
er
e 
yo
u 
af
ra
id
 o
f t
he
 fu
tu
re
?b
0.
08
−
0.
22
0.
25
0.
63
I t
hi
nk
 a
bo
ut
 h
ow
 I 
w
ill
 d
ie
.b
−
0.
02
0.
15
0.
22
0.
58
In
 th
e 
pa
st 
7 
da
ys
 to
 w
ha
t d
eg
re
e 
di
d 
yo
u 
ha
v
e 
to
 p
us
h 
yo
ur
se
lf 
to
 k
ee
p 
go
in
g?
a
0.
07
0.
03
0.
11
0.
45
I f
ee
l i
n 
co
nt
ro
l o
f m
y 
lif
e.
b
0.
35
0.
14
0.
02
0.
40
I a
m
 c
on
ce
rn
ed
 th
at
 I 
w
o
n
't 
be
 a
bl
e 
to
 h
av
e 
ch
ild
re
n.
a
0.
14
0.
18
0.
15
0.
08
N
ot
e.
Qual Life Res. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Carlozzi et al. Page 21
a r
es
po
ns
e 
op
tio
ns
 =
 n
ot
 a
t a
ll,
 a
 li
ttl
e 
bi
t, 
so
m
ew
ha
t, 
qu
ite
 a
 b
it,
 v
er
y 
m
uc
h
b r
es
po
ns
e 
op
tio
ns
 =
 n
ev
er
,
 
ra
re
ly
,
 
so
m
et
im
es
, o
fte
n,
 a
lw
ay
s.
Qual Life Res. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Carlozzi et al. Page 22
Ta
bl
e 
2
H
D
QL
IF
E 
M
ea
nin
g a
nd
 Pu
rpo
se 
Ite
m 
Pa
ra
m
et
er
s
It
em
Sl
op
e
T1
T2
T3
T4
I f
ee
l c
om
fo
rta
bl
e 
ta
lk
in
g 
ab
ou
t m
y 
de
at
h.
0.
84
−
2.
72
−
1.
60
−
0.
10
1.
21
I a
m
 m
ak
in
g 
th
e 
m
os
t o
ut
 o
f t
he
 ti
m
e 
I h
av
e 
le
ft.
2.
64
−
2.
26
−
1.
68
−
0.
83
−
0.
01
M
y 
lif
e 
ha
s m
ea
ni
ng
.
2.
26
−
2.
78
−
2.
13
−
1.
11
−
0.
26
I f
in
d 
m
ea
ni
ng
 in
 m
y 
ill
ne
ss
.
0.
91
−
1.
27
−
0.
64
0.
69
1.
78
Th
er
e 
ar
e 
im
po
rta
nt
 th
in
gs
 th
at
 I 
sti
ll 
w
an
t t
o 
do
 w
ith
 m
y 
lif
e.
1.
30
−
3.
26
−
2.
44
−
1.
28
−
0.
34
I a
m
 sa
tis
fie
d 
w
ith
 m
y 
ab
ili
ty
 to
 m
ak
e 
th
e 
m
os
t o
ut
 o
f t
he
 ti
m
e 
th
at
 I 
ha
v
e 
le
ft.
3.
66
−
1.
87
−
1.
40
−
0.
71
0.
01
I l
iv
e 
m
y 
lif
e 
to
 th
e 
fu
lle
st
.
4.
75
−
1.
91
−
1.
48
−
0.
65
0.
11
N
ot
e.
 It
em
s t
ha
t a
re
 b
ol
de
d 
w
er
e 
se
le
ct
ed
 fo
r i
nc
lu
sio
n 
in
 th
e 
fin
al
, 4
-it
em
 sh
or
t f
or
m
Qual Life Res. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Carlozzi et al. Page 23
Ta
bl
e 
3
H
D
QL
IF
E 
Co
nc
ern
 w
ith
 D
ea
th 
an
d D
yin
g I
tem
 Pa
ra
m
et
er
s
C
on
ce
rn
 w
ith
 D
ea
th
 a
nd
 D
yi
ng
 It
em
Sl
op
e
T1
T2
T3
T4
In
 th
e 
pa
st
 7
 d
ay
s h
ow
 o
fte
n 
di
d 
yo
u
 th
in
k 
ab
ou
t e
nd
in
g 
yo
u
r 
lif
e?
1.
48
1.
28
2.
02
2.
73
3.
38
In
 th
e 
pa
st 
7 
da
ys
 h
ow
 o
fte
n 
di
d 
yo
u 
be
co
m
e 
sa
d 
w
he
n 
yo
u 
th
ou
gh
t a
bo
ut
 th
e 
en
d 
of
 y
ou
r l
ife
?
2.
21
−
0.
07
0.
59
1.
52
2.
12
In
 th
e 
pa
st 
7 
da
ys
 h
ow
 o
fte
n 
w
er
e 
yo
u 
pr
eo
cc
up
ie
d 
w
ith
 th
ou
gh
ts 
of
 d
yi
ng
?
4.
55
0.
32
1.
00
1.
71
2.
18
In
 th
e 
pa
st
 7
 d
ay
 h
ow
 o
fte
n 
di
d 
yo
u
 fe
el
 a
nx
ie
ty
 th
at
 y
o
u
 w
o
u
ld
 d
ie
?
2.
50
0.
17
0.
87
1.
70
2.
24
In
 th
e 
pa
st
 7
 d
ay
s h
ow
 o
fte
n 
di
d 
yo
u
 th
in
k 
ab
ou
t d
yi
ng
?
4.
57
0.
12
0.
84
1.
60
2.
23
In
 th
e 
pa
st
 7
 d
ay
s h
ow
 o
fte
n 
di
d 
yo
u
 th
in
k 
ab
ou
t y
o
u
r 
o
w
n
 d
ea
th
?
4.
57
−
0.
02
0.
80
1.
61
2.
18
In
 th
e 
pa
st 
7 
da
ys
 h
ow
 o
fte
n 
di
d 
yo
u 
ta
lk
 to
 o
th
er
s a
bo
ut
 y
ou
r o
w
n
 d
ea
th
?
1.
62
0.
28
1.
27
2.
57
3.
65
In
 th
e 
pa
st 
7 
da
ys
 h
ow
 o
fte
n 
w
er
e 
yo
u 
w
o
rr
ie
d 
yo
ur
 il
ln
es
s w
o
u
ld
 g
et
 w
o
rs
e?
1.
77
−
0.
98
−
0.
19
0.
83
1.
57
In
 th
e 
pa
st 
7 
da
ys
 h
ow
 o
fte
n 
w
er
e 
yo
u 
pr
eo
cc
up
ie
d 
w
ith
 th
ou
gh
ts 
of
 d
ea
th
?
3.
64
0.
37
1.
02
1.
81
2.
41
In
 th
e 
pa
st
 7
 d
ay
s h
ow
 o
fte
n 
di
d 
yo
u
 w
o
rr
y 
ab
ou
t h
ow
 y
o
u
r 
fa
m
ily
 w
o
u
ld
 c
op
e 
w
ith
 y
o
u
r 
de
at
h?
1.
59
−
0.
65
0.
12
1.
07
1.
73
In
 th
e 
pa
st 
7 
da
ys
 h
ow
 o
fte
n 
w
er
e 
yo
u 
af
ra
id
 o
f t
he
 fu
tu
re
?
1.
82
−
0.
61
0.
12
1.
20
2.
13
I t
hi
nk
 a
bo
ut
 h
ow
 I 
w
ill
 d
ie
.
1.
98
−
0.
90
0.
20
1.
56
2.
21
N
ot
e.
 It
em
s t
ha
t a
re
 b
ol
de
d 
w
er
e 
se
le
ct
ed
 fo
r i
nc
lu
sio
n 
on
 th
e 
6-
ite
m
 sh
or
t f
or
m
.
Qual Life Res. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Carlozzi et al. Page 24
Table 4
HDQLIFE Meaning and Purpose SF Summed Score to t Score Conversion Table
Meaning and Purpose SF Summed Score Meaning and Purpose t Score
4 22
5 25
6 27
7 29
8 31
9 33
10 35
11 37
12 39
13 40
14 42
15 44
16 46
17 48
18 51
19 54
20 61
Note. SF = 4-item Short Form
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Table 5
HDQLIFE Concern with Death and Dying SF t Score Conversion Table
Death and Dying SF Summed Score Death and Dying t Score
6 36
7 41
8 44
9 46
10 48
11 51
12 52
13 54
14 56
15 57
16 59
17 60
18 61
19 63
20 64
21 65
22 67
23 68
24 70
25 71
26 73
27 74
28 76
29 77
30 80
Note. SF = 6-item Short Form
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